OGN vs PFE

For growth investors, Pfizer Inc.

(PFE) is the stronger pick with -1. 6% revenue growth year-over-year, versus -2. 9% for Organon & Co. (OGN). Organon & Co. (OGN) offers the better valuation at 18. 5x trailing P/E (3. 9x forward), making it the more compelling value choice. Analysts rate Organon & Co. (OGN) a "Hold" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Organon & Co.

(OGN) is the cheapest at 18. 5x versus Pfizer Inc. at 19. 5x. On forward P/E, Organon & Co. is actually cheaper at 3. 9x.

Over the past 5 years, Pfizer Inc.

(PFE) delivered a total return of -13. 3%, compared to -47. 1% for Organon & Co. (OGN). Over 10 years, the gap is even starker: PFE returned +29. 6% versus OGN's -47. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pfizer Inc.

(PFE) is the lower-risk stock at 0. 54β versus Organon & Co. 's 1. 10β — meaning OGN is approximately 103% more volatile than PFE relative to the S&P 500.

By revenue growth (latest reported year), Pfizer Inc.

(PFE) is pulling ahead at -1. 6% versus -2. 9% for Organon & Co. (OGN). On earnings-per-share growth, the picture is similar: Pfizer Inc. grew EPS -3. 5% year-over-year, compared to -78. 4% for Organon & Co.. Over a 3-year CAGR, OGN leads at 0. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pfizer Inc.

(PFE) is the more profitable company, earning 12. 4% net margin versus 3. 0% for Organon & Co. — meaning it keeps 12. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PFE leads at 24. 7% versus 20. 7% for OGN. At the gross margin level — before operating expenses — PFE leads at 70. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Organon & Co.

(OGN) trades at 3. 9x forward P/E versus 8. 9x for Pfizer Inc. — 5. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PFE: 3. 0% to $27. 27.

In this comparison, PFE (6.

5% yield) pays a dividend. OGN does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Pfizer Inc.

(PFE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 6. 5% yield). Both have compounded well over 10 years (PFE: +29. 6%, OGN: -47. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: OGN is a small-cap quality compounder stock; PFE is a mid-cap income-oriented stock. PFE pays a dividend while OGN does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.